CN113557059A - 角膜疾病治疗剂 - Google Patents

角膜疾病治疗剂 Download PDF

Info

Publication number
CN113557059A
CN113557059A CN202080019942.8A CN202080019942A CN113557059A CN 113557059 A CN113557059 A CN 113557059A CN 202080019942 A CN202080019942 A CN 202080019942A CN 113557059 A CN113557059 A CN 113557059A
Authority
CN
China
Prior art keywords
group
corneal
formula
therapeutic agent
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080019942.8A
Other languages
English (en)
Chinese (zh)
Inventor
深泽菜月
西野泰斗
渡边里奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of CN113557059A publication Critical patent/CN113557059A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080019942.8A 2019-03-12 2020-03-11 角膜疾病治疗剂 Pending CN113557059A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019044854 2019-03-12
JP2019-044854 2019-03-12
PCT/JP2020/010465 WO2020184605A1 (ja) 2019-03-12 2020-03-11 角膜疾患治療剤

Publications (1)

Publication Number Publication Date
CN113557059A true CN113557059A (zh) 2021-10-26

Family

ID=72427179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080019942.8A Pending CN113557059A (zh) 2019-03-12 2020-03-11 角膜疾病治疗剂

Country Status (5)

Country Link
US (1) US20220133659A1 (https=)
EP (1) EP3939663A4 (https=)
JP (1) JPWO2020184605A1 (https=)
CN (1) CN113557059A (https=)
WO (1) WO2020184605A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144755A1 (en) * 2006-06-16 2010-06-10 Glaxo Group Limited Novel Compounds
JP2011057667A (ja) * 2009-08-12 2011-03-24 Taisho Pharmaceutical Co Ltd 角結膜疾患の予防又は治療剤
WO2019022222A1 (ja) * 2017-07-28 2019-01-31 日産化学株式会社 培地添加用組成物及び培地添加用化合物並びにそれらを用いた細胞又は組織の培養方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5761827B2 (ja) 2011-07-15 2015-08-12 国立大学法人大阪大学 角膜内皮細胞の調製方法
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
WO2015080297A1 (en) * 2013-11-27 2015-06-04 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
KR101815390B1 (ko) * 2016-09-08 2018-01-04 충남대학교산학협력단 세포 배양용 배지 조성물
JP6534006B2 (ja) 2017-09-01 2019-06-26 株式会社アカギ 複数の配管吊下支持具を具備する配管の吊下支持構造
TW202005643A (zh) 2018-06-08 2020-02-01 日商日產化學股份有限公司 激酶抑制劑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144755A1 (en) * 2006-06-16 2010-06-10 Glaxo Group Limited Novel Compounds
JP2011057667A (ja) * 2009-08-12 2011-03-24 Taisho Pharmaceutical Co Ltd 角結膜疾患の予防又は治療剤
WO2019022222A1 (ja) * 2017-07-28 2019-01-31 日産化学株式会社 培地添加用組成物及び培地添加用化合物並びにそれらを用いた細胞又は組織の培養方法

Also Published As

Publication number Publication date
WO2020184605A1 (ja) 2020-09-17
JPWO2020184605A1 (https=) 2020-09-17
EP3939663A1 (en) 2022-01-19
EP3939663A4 (en) 2022-05-04
US20220133659A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
US20210253518A1 (en) Kinase inhibitor
JP7205473B2 (ja) 培地添加用組成物及び培地添加用化合物並びにそれらを用いた細胞又は組織の培養方法
US11844755B2 (en) Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium
EP3733177B1 (en) Composition for protecting cornea
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
US20030087949A1 (en) Indolylpyrrole derivatives and cell death inhibitors
CN113348017A (zh) 酰肼化合物及激酶抑制剂
CN113557059A (zh) 角膜疾病治疗剂
US20210009941A1 (en) Composition that contains polylysine analog and promotes cell growth
CN105001296B (zh) 一种一氧化氮供体型地塞米松及制备方法与用途
JPWO2020067477A1 (ja) パラクライン因子生産促進用培地添加剤
CN101519385B (zh) 具有促进干细胞增殖作用的小分子化合物及其用途
JP4566130B2 (ja) 角膜知覚回復剤
JP6381605B2 (ja) 脳卒中治療用のイリドイド配糖体類化合物、その医薬組成物及びその使用方法
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
JP2022035392A (ja) 毛包細胞の増幅方法
CN112472695A (zh) 他汀类化合物在制备促进哺乳动物精原干细胞再生功能的药物中的应用
JP2023007595A (ja) 心筋細胞増殖促進剤
US7390826B2 (en) Inhibitors of animal cell motility and growth
JP2022035391A (ja) 肝臓前駆細胞の増幅方法
WO2019022152A1 (ja) ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
US20230365545A1 (en) New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
US20120053214A1 (en) The little molecule compound which used for promoting the stem cells hyperplasia and the use thereof
CN117402173A (zh) 一种新型异香豆素类衍生物及其制备方法与应用
KR20070005345A (ko) ２,５-디히드로-４-알킬-２,５-디옥소퓨란 유도체 및이것의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211026